CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03381183
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:53.279881+00:00
- Published At
- 2025-12-05T00:00:00+00:00
- Record Updated At
- 2025-12-05
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Metastatic Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma", "Oropharynx Squamous Cell Carcinoma", "Paranasal Sinus Squamous Cell Carcinoma", "Hypopharynx Squamous Cell Carcinoma", "Larynx Squamous Cell Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-05"- protocolSection.identificationModule.nctId
"NCT03381183"- protocolSection.identificationModule.officialTitle
"A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.